Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, articles of association on November 3, 20068 Nov 2006
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise3 Nov 2006
Genmab, quarterly report Q331 Oct 2006
Genmab, Announces Results for the First Nine Months of 200631 Oct 2006
Genmab, Initiates Combination Study of HuMax-EGFr with Chemo-Radiation24 Oct 2006
Genmab, hosts Research, Development and Business Update18 Oct 2006
Genmab, articles of association on September 19, 2006 II9 Oct 2006
Genmab, completes accrual in HuMax-CD20 Phase II RA Study
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
22 Sept 2006
Genmab, articles of association on September 19, 200622 Sept 2006
Genmab, Grant of Warrants in Genmab A/S20 Sept 2006
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise20 Sept 2006
Genmab, Report Pursuant to Section 28a of the Danish Securities Trading Act20 Sept 2006
  • Previous
  • 1
  • More pages
  • 124
  • 125
  • 126
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863